For nmHSPC, 10-year disease progression rates of 13% and all-cause mortality rates of 21% align with estimates by Yamoah et al,12 who found a 10% 10-year cumulative incidence for metastatic disease using a treatment-stratified model adjusting for age, PSA level, Gleason score, time to treatment, ADT use, and diagnosis year. The gene discussed is KLK3; the disease is metastatic neoplasm.